Bionomics Ltd ADR (BNOX)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective...  negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.  Read more

• CEO, President & Director

  Dr. Spyridon Papapetropoulos M.D., Ph.D.

• CEO, President & Director

  Dr. Spyridon Papapetropoulos M.D., Ph.D.

• Headquarters

  Eastwood, SA

• Website

  https://www.bionomics.com.au